Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 9/20 | 0.73 |
| ▸ | AVPR1B | P47901 | 9/20 | 0.73 |
| ▸ | OXTR | P30559 | 7/20 | 0.72 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15511399 | 0.92 | AVPR1A (0.78) | AVPR1AAVPR1BOXTRAVPR2 | |
| Vasotocin SCHEMBL15511347 | 0.91 | OXTR (0.86) | AVPR1AAVPR1BOXTRAVPR2 | |
| Vasotocin SCHEMBL15511393 | 0.91 | OXTR (0.86) | AVPR1AAVPR1BOXTRAVPR2 | |
| Vasotocin SCHEMBL13331 | 0.91 | OXTR (0.86) | AVPR1AAVPR1BOXTRAVPR2 | |
| Argiprestocin SCHEMBL30424966 | 0.91 | OXTR (0.86) | AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL15511428 | 0.88 | OXTR (0.82) | AVPR1AAVPR1BOXTRAVPR2 | |
| SCHEMBL29618038 | 0.85 | OXTR (0.86) | AVPR1AAVPR1BOXTRAVPR2 | |
| Selepressin SCHEMBL19712231 | 0.85 | OXTR (0.82) | AVPR1AAVPR1BOXTRAVPR2 | |
| Selepressin SCHEMBL28487360 | 0.85 | OXTR (0.82) | AVPR1AAVPR1BOXTRAVPR2 | |
| Selepressin SCHEMBL19712230 | 0.85 | OXTR (0.82) | AVPR1AAVPR1BOXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| EP-3423091-B1 | COMPOSITIONS AND METHODS FOR INDUCING HIV-1 ANTIBODIES | UNIV DUKE (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12305211-B2 | Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases | NORTHWESTERN UNIVERSITY (US) | 2025-05-20 | — | — | US | disclosed |
| US-20250144050-A1 | AMINOTHIOL-CONJUGATES, COMPOSITIONS, AND METHODS OF USE THEREOF | THE BURLINGTON HC RESEARCH GROUP, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025078698-A1 | FUSION PROTEINS FOR THE TREATMENT OF VIRAL INFECTIONS | FUNDACIÓN INVESTIGACIÓN BIOMÉDICA HOSPITAL UNIVERSITARIO 12 DE OCTUBRE (ES) | 2025-04-17 | — | — | WO | disclosed |
| US-20250073328-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HIV INFECTION | US GOV VETERANS AFFAIRS (US) | 2025-03-06 | — | — | US | disclosed |
| CN-119523989-A | Compounds and compositions for treating microwave radiation induced brain injury by modulating GABA-alpha 5 | 中国人民解放军军事科学院军事医学研究院 | 2025-02-28 | — | — | CN | disclosed |
| US-20240390482-A1 | HIV-1 ENVELOPE GLYCOPEPTIDE NANOPARTICLES AND THEIR USES | UNIV DUKE (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240376510-A1 | DESIGN OF PROTEIN GLYCOSYLATION SITES BY RAPID EXPRESSION AND CHARACTERIZATION OF N-GLYCOSYLTRANSFERASES | NORTHWESTERN UNIVERSITY | 2024-11-14 | — | — | US | disclosed |
| CN-118859787-A | Method for learning and calibrating automobile seat position | 昌辉汽车电气系统（安徽）有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230140293-A1 | COMPOSITIONS COMPRISING MODIFIED HIV ENVELOPES | DUKE UNIVERSITY | 2023-05-04 | — | — | US | disclosed |
| CN-218829874-U | Frequency hopping filter | 上海鸿晔电子科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2023028316-A1 | AMINOTHIOL-CONJUGATES, COMPOSITIONS, AND METHODS OF USE THEREOF | THE BURLINGTON HC RESEARCH GROUP, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022192262-A1 | HIV-1 ENVELOPE GLYCOPEPTIDE NANOPARTICLES AND THEIR USES | DUKE UNIVERSITY (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-3166607-B1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220235389-A1 | Design of Protein Glycosylation Sites by Rapid Expression and Characterization of N-Glycosyltransferases | NORTHWESTERN UNIVERSITY (US) | 2022-07-28 | — | — | US | disclosed |
| US-11318197-B2 | Compositions and methods for inducing HIV-1 antibodies | DUKE UNIVERSITY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20220041650-A1 | PURIFICATION METHOD FOR RECOMBINANT PROTEINS AND NANOPARTICLES | UNIV DUKE (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250073328-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HIV INFECTION | CD4, C9, C1S | AVPR1A 1122/4885AVPR1B 1576/4885OXTR 3881/4885 |
| US-20250144050-A1 | AMINOTHIOL-CONJUGATES, COMPOSITIONS, AND METHODS OF USE THEREOF | TIAL1, SLC7A11, MGMT | AVPR1A 4472/4885AVPR1B 4578/4885OXTR 2542/4885 |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | AVPR1A 1196/4885AVPR1B 926/4885OXTR 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.